Kornimate/medical-research-clean huggingface dataset:
peculiarities of pain in patients with mine-explosive wounds depending on the localization of the wound at the stages of treatment

Conditions: Chronic Pain

Summary: mine-explosive wounds in the general structure of combat sanitary losses reach 25%. they are characterized by significant damage resulting in high intensity pain. in patients who received mine-explosive injuries in the conditions of hostilities, such pain has its own unique features. it is necessary to pay more attention to the problem of pain treatment in patients of this category, because about 87.2% of cases have negative results of treatment - it becomes chronic.

over the last ten years, the amount of pathology caused by mine-explosive devices has increased significantly. mine-explosive wounds in the general structure of combat sanitary losses reach 25%. they often have a combined character. such an injury must be considered as a multifactorial injury resulting from the combined impact on a person of a shock wave, gas jets, flames, toxic products, fragments of the hull, secondary projectiles, which cause severe injuries in the area of direct damage and the body as a whole. mine-explosive injuries are characterized by multiple, combined or combined injuries with a high degree of severity - 8-10%. also, even in peacetime, terrorists often use powerful explosive devices. here, the mortality rate is 10-20% of the total number of injured, and 80-90% suffer from the consequences - mine-explosive injuries. compared to the wars of the past, the number of seriously wounded with combined injuries has increased to 25-30%. this is primarily due to the use of high-precision ammunition and mine-explosive ammunition. in general, multiple and combined damage in local conflicts today is 25-62%. lethality in case of mine-explosive injury reaches 37-41.4%. the mortality rate among the wounded with mine-explosive injuries who were admitted to the stage of qualified medical care was 17.4%, more than half of the wounded died as a result of blood loss. in 63.7%, death occurs in the first 24 hours after injury.the direct and most frequent causes are shock and blood loss (49.1%), destruction of vital organs (28.4%). about 90% of all combat deaths occur before the wounded reaches the first stage of treatment. the peculiarities of pain in patients with mine-explosive wounds depending on the localization of the wound at the stages of treatment need to be studied, because the subjective feelings and emotional experiences experienced by patients during the wounding in combat conditions through the prism of psychological disorders have their own characteristics. since in 87.2% of cases it is not possible to achieve a positive result of treatment, the data of our study will play an important role in their treatment.

Eligibility criteria:
inclusion criteria: * the presence of gunshot wounds exclusion criteria: * no gunshot wounds

Keywords: pain, wounds, stages of treatment
in vitro study of peripheral blood mononuclear cell function in healthy individuals and patients

Conditions: Cell Function

Summary: peripheral blood mononuclear cells (pbmc) will be collected from healthy volunteers and patients who present with different diseases that involve or implicate the immune system dysregulation (hiv infection, autoimmune diseases and cancer). these pbmc will be studied in vitro for a number of functional parameters, including generating soluable factors that inhibit hiv infection, developing patterns of immune dysregulation, and inducing apoptotic t cell death. the purpose of such studies is to obtain insight into the mechanisms of natural resistance to viral infections, aids pathogenesis, and disease-induced immune dysregulation.

peripheral blood mononuclear cells (pbmc) will be collected from healthy volunteers and patients who present with different diseases that involve or implicate the immune system dysregulation (hiv infection, autoimmune diseases and cancer). these pbmc will be studied in vitro for a number of functional parameters, including generating soluable factors that inhibit hiv infection, developing patterns of immune dysregulation, and inducing apoptotic t cell death. the purpose of such studies is to obtain insight into the mechanisms of natural resistance to viral infections, aids pathogenesis, and disease-induced immune dysregulation.

Eligibility criteria:
* inclusion criteria: greater than or equal to 18 years old. documented hiv infection by current dod criteria (1 elisa, 2 confirmatory western blot) or by one of the following tests; dna pcr, rna pcr, p24 antigen test, viral culture assay. cd4 lymphocyte cell count greater than 300 mm(3). exclusion criteria: unable to provide informed consent. unable to meet the minimum (150 days) and maximum (395 days) research visit interval requirements.

Keywords: cellular immunity hiv-infected immune deficiency cancer transplantation
critical respiratory events in children requiring naloxone: naloxone use as opioid safety measure

Conditions: Opioid Induced Respiratory Depression

Summary: opioids are the mainstay of analgesia in hospitalized children but opioid therapy is associated with life-threatening respiratory depression requiring antagonism with naloxone. hence, it is hypothesized that naloxone requirement can be used as a quality measure of opioid safety. a retrospective medical chart review of 95 patients, who received naloxone for life threatening events, from june 2006-2012, is planned, to identify significant factors associated with risk for opioid induced respiratory depression and formulation of preventive strategies.


Eligibility criteria:
inclusion criteria: * any gender, age or race * administered naloxone for opioid induced respiratory depression exclusion criteria: * any one who did not require naloxone for opioid induced respiratory depression

Keywords: naloxone children opioid respiratory depression safety
a trial of pre-operative chemoradiotherapy using capecitabine, radiation & cetuximab, in rectal cancer

Conditions: Colon Rectal Cancer Duke Stage Stageval

Summary: a pilot trial of pre-operative chemoradiotherapy using capecitabine (xelodaâ), external beam radiation and cetuximab (erbitux®) followed by definitive surgery in patients with localized (non-metastatic) rectal cancer

its a pilot study of pre-op chemotherapy and rt utilizing capecitabine, xrt and cetuximab in pts with locally advanced rectal carcinoma.

Eligibility criteria:
inclusion criteria: * patients with localized non-metastatic rectal cancer exclusion criteria: * patients with diagnosis other than localized non-metastatic rectal cancer

Keywords: rectal cancer
deep brain stimulation for laryngeal dystonia: from mechanism to optimal application

Conditions: Laryngeal Dystonia; Adductor Spastic Dysphonia of Dystonia

Summary: deep brain stimulation (dbs) is a neurosurgical procedure used to treat tremors, and dystonia. this study will enroll people who have a form of focal dystonia that affects their vocal cords called adductor laryngeal dystonia (adld). participants will undergo deep brain stimulation surgery to treat laryngeal dystonia as part of their clinical care. before surgery, as part of the study they will have specialized testing to study the movement of the vocal cords, as well as functional magnetic resonance imaging (fmri). while in the operating room, researchers will examine brain waves to better understand how faulty brain firing patterns lead to dystonia. after surgery, and activation of the deep brain stimulator, participants will repeat speech testing and vocal cord imaging as well as magnetic resonance imaging (mri).


Eligibility criteria:
inclusion criteria: * patients with adld and adld plus tremor, as diagnosed by routine clinical examination by laryngologist, speech language pathologist, and neurologist. * patients undergoing globus pallidus interna (gpi) deep brain stimulation (dbs) for adld with tremor * age range of 18-80 years * native speakers of american english will be recruited since there are known differences in voice and neural signals of native and non-native speakers * no evidence for dementia as assessed by neurologist. * no evidence for severe untreated mood disorder as assessed by neurologist, or as evident on self-report (beck depression inventory-ii score \> 29, beck anxiety inventory score \> 26. * at least 3 months since last botulinum toxin injection and the patients would need to be fully symptomatic with no residual effects of botulinum toxin on voice quality. exclusion criteria: * individuals younger than 18 years and older than 80 years of age. * women who plan to become pregnant during the study period or are currently breastfeeding. * prior history of stroke, brain surgery, or other neurological disorder besides the one under study. * prior laryngeal framework surgeries or other disorders affecting the vocal folds * patients who are asymptomatic due to treatment with botulinum toxin into the vocal folds. * presence of ferromagnetic implants and cardiac implants that would be contraindicated to mri * gagging or discomfort that would preclude the placement of the endoscope to visualize the larynx * dementia, severe depression or severe anxiety. * any clinical condition or medication judged by the investigators to potentially preclude the patient from safely completing awake brain surgery and research protocols.

Keywords: deep brain stimulation
novel therapeutics and endothelial dysfunction in t1dm patients

Conditions: Endothelial Dysfunction; Diabetes Mellitus, Type 1; Biomarkers; Endothelial Progenitor Cells; SGLT 2 Inhibitors; Incretins; Glucose Excursions; FMD; FPF; Arterial Stiffness

Summary: the aim of study is impact of additional treatment with new antidiabetic drugs (semaglutide or empagliflozine) compared to control group in t1dm patients - impact on endothelial function measured by fmd and fpf, arterial stiffness - measured by pwv, inflammatory biomarkers, markers of oxidative stress and endothelial progenitor cells (cd 34+/vdrl2, cd 133+/vdrl2) and correlation with glucovariability or time in range, measured with cgm system.


Eligibility criteria:
inclusion criteria: * t1dm * hba1c\<=9% * prone to cgm system * 20 - 70 years exclusion criteria: * hba1c \>9%, * bmi\<22, * pregnancy or lactation, * known hypersensitivity to study drug, * malignant disease ( excluded \>5 years disease free, bazocellular or planocellular ca of skin), * liver cirrhosis child c, * egfr\<60 ml/min, * chronic inflammatory disease, * proliferative diabetic rethinopathy, * men or medullary thyroid cancer in familly, * concomitant drugs with influence on glycemia and antiinflammatory influence (corticosteroids, immunosupresive therapy), * major cardiovascular event last 2 months ( stroke, mi)
effect of rye bread breakfasts on eight hour satiety ratings

Conditions: Obesity

Summary: the aim of the present study was to investigate subjective appetite during 8 hours after intake of iso-caloric rye bread breakfasts varying in dietary fiber composition and content.

energy-dense foods that require little effort to consume and that are rapidly digested may cause passive over-consumption by failure to provide a feeling of fullness corresponding to the energy content. a diet that is predominantly based on such foods may lead to overweight. it is therefore important to identify properties of foods that facilitate energy balance by creating a high satiety per calorie. a number of studies have confirmed that foods naturally rich in dietary fiber promote the feeling of fullness and reduce hunger in the short term.

Eligibility criteria:
inclusion criteria: * age between 20 and 60 years * body mass index (bmi) 18-27 kg/m2 * a habit of consuming breakfast, lunch and dinner everyday * fasting plasma glucose 4.0-6.1 mmol/l * haemoglobin (hb) in men 130-170 g/l, in women 120-150 g/l * thyroid-stimulating hormone (tsh) 0.3-4.0 mle/l * willingness to comply with the study procedures exclusion criteria: * intake of medicine likely to affect appetite or food intake * any medical condition involving the gastrointestinal tract * eating disorder * smoking * consumption of more than three cups of coffee per day * change in body weight of more than 10% three months prior to screening * consumption of any restricted diet such as vegan, gluten-free, slimming etc. * pregnancy, lactation or wish to become pregnant during the study period

Keywords: rye bread satiety breakfast
efficacy of 60-minute versus 90-minute sessions in treating ptsd using prolonged exposure

Conditions: Posttraumatic Stress Disorder; PTSD

Summary: the purpose of this study is to determine whether 60-minute sessions of prolonged exposure (pe) are as effective as the standard 90-minute session for treating posttraumatic stress disorder (ptsd). participants will include patients ages 18 or older with a current diagnosis of ptsd who are seeking treatment in our clinic. patients who have current substance dependence, psychosis, and suicidal ideation with intent and plan may not be suitable for receiving pe and may be offered another treatment or referred to a different treatment center. participants will be randomized to receive either the 90- minute or 60-minute pe session. a blind evaluator will assess for pre-treatment, post-treatment, and follow-up levels of symptom severity using the ptsd symptoms scale interview (pss-i). participants will attend weekly treatment sessions with any of our faculty members and will complete self-report measures at every session (see below).


Eligibility criteria:
inclusion criteria: * primary diagnosis of ptsd * recommended by therapist to receive prolonged exposure therapy exclusion criteria: * current substance dependence, psychosis, suicidal ideation with intent and plan, or other psychiatric problems warranting immediate clinical attention or would interfere with prolonged exposure therapy

Keywords: posttraumatic stress disorder ptsd prolonged exposure therapy cognitive behavioral therapy
vfi in healthy vessels

Conditions: Carotid Artery Stenosis; Superficial Femoral Artery Stenosis

Summary: there is a wealth of evidence implicating the important role of blood flow throughout all stages of the process of atherogenesis. two locations along the vascular tree at which atherosclerotic plaques are typically found are the carotid artery (ca) and the superficial femoral artery (sfa). nowadays, ultrasound is the technique of choice for assessing the vascular condition in the ca and sfa. however, clinically used ultrasound techniques show a large variability in estimating the blood flow velocity, due to multiple limitations. with the advent of ultrafast ultrasound imaging, (almost) all elements of the transducer can be activated simultaneously. these so-called plane wave acquisition acquires thousands of images per second and makes continuous tracking of blood flow velocities in all directions in the field of view possible. this high-frame-rate acquisition opened up new possibilities for blood flow imaging at the ca and sfa, such as blood speckle tracking (bst) and ultrasound particle image velocimetry (echopiv). both these vector flow imaging (vfi) techniques enable the quantification of 2d blood flow velocity profiles, where bst uses no contrast agents compared to echopiv. beside these novel ultrasound based techniques, 4d phase contrast magnetic resonance imaging (4d flow mri) enables a non-invasive quantification of the 4d blood flow velocity profiles (3d + time) and can be used as reference standard for blood flow assessments in-vivo. we therefore aim to evaluate the performance of both vfi techniques in comparison to 4d flow mri measurements in the ca and sfa of healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy male or female, without cardiovascular and pulmonary medical history and without the use of medication for cardiovascular risk factors * age between 20-30 year or 65-75 years old * willingness to undergo a 4d flow mri scan and us examinations * informed consent form understood and signed, and agrees to the hospital visit exclusion criteria: * hypersensitivity to the active substance(s) or any of the excipients in sonovue * pregnancy * mri exclusion criteria (such as presence of pacemaker, cerebral vascular clips, claustrophobia)

Keywords: vector flow imaging ultrasound particle image velocimetry blood speckle tracking 4d flow mr
a study of bone turnover markers in post-menopausal women with osteoporosis treated with monthly boniva (ibandronate)

Conditions: Post Menopausal Osteoporosis

Summary: this study will determine the rapidity of suppression of the bone resorption marker sctx in post-menopausal women with osteoporosis.other bone turnover markers will also be evaluated. patients will be randomised to either monthly boniva 150mg or placebo, in combination with vitamin d and calcium supplementation. the anticipated time on study treatment is approximately 7 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * women who have been newly diagnosed with post-menopausal osteoporosis, requiring treatment; * naive to bisphosphonate treatment,or had bisphosphonate treatment for a maximum of 3 months, at least 5 years before screening. exclusion criteria: * patients on hormone replacement therapy (hrt) within the last 3 months; * patients on other osteoporosis medication within the last 3 months; * sctx below lower limit, or above 3 times the upper limit, of normal premenopausal level; * hypersensitivity to any component of ibandronate; * contraindication for calcium or vitamin d therapy; * history of major gastrointestinal upset; * malignant disease diagnosed within the previous 10 years (except resected basal cell cancer).
diagnosis and intervention of complicated twin diseases

Conditions: Twin Diseases

Summary: fetal medicine in china is still a new, young discipline, and the development is very rapid. after nearly 10 years of development, the clinical diagnosis and treatment guidelines of some complicated twin diseases has been established , but they are still needed to be improved. through this study, the investigators expect to achieve better prediction indicators and early intrauterine precise diagnosis of complicated twin diseases. also, better procedures of implementing effective intrauterine intervention and assessing the safety and effectiveness of intrauterine intervention are anticipated to be established.

a better guideline for complicated twin diseases are anticipated to be established in china. molecular genetics and imaging technology are applied to evaluate the outcome and prognosis of intrauterine intervention for complex twin diseases. 3d printing technology is used to assist the preoperative evaluation of fetal intrauterine intervention. better fetal intrauterine intervention technique and prognosis evaluation are expected to be established.

Eligibility criteria:
inclusion criteria: * pregnancy women with complicated twin diseases who are able to withstand intrauterine treatment and consent informed. exclusion criteria: * pregnancy women who refuse intrauterine treatment.
sofosbuvir/ombitasvir/paritaprevir/ ritonavir and ribavirin for hepatitis c virus genotype 4 patients

Conditions: Chronic Hepatitis C Virus Infection

Summary: enrolled participants were treated orally with sof plus a fixed dose combination of obv/ptv/r plus rbv.

enrolled participants were treated orally with sof plus a fixed dose combination of sofosbuvir/ombitasvir/paritaprevir/ ritonavir plus ribavirin (obv/ptv/r plus rbv), which was administered orally based on the participants' tolerability. the primary end point was a sustained virological response (hcv rna level \< 15 iu/ ml), observed 12 weeks after the end of the treatment (svr12).

Eligibility criteria:
inclusion criteria: * the experienced participants who were treated previously with (sof/dcv) , (sof/smv), (sof/rbv), or (sof/peginf/rbv). * the presence of compensated liver cirrhosis was documented by ultrasonographic examination, liver biopsy, results of fibroscan or fib-4 score, and laboratory markers, like fib-4 \> 3.25 (advanced fibrosis or cirrhosis), albumin \ 1.2, and also confirmed by clinical characteristics such as lower limb edema, splenomegaly, esophageal varices. exclusion criteria: * liver disease of non-hcv gt4 etiology, coinfection with hepatitis b or hiv * poorly controlled diabetes (hba1c \> 8) * participants, hepatocellular carcinoma, a history of extrahepatic malignancy in the 5 years prior to the study * renal failure * evidence of hepatic decompensation * blood picture abnormalities such as anemia (hemoglobin concentration of \< 10 g/dl) * thrombocytopenia (platelets count \< 50,000 cells/mm3). * major severe illness such as congestive heart failure and respiratory failure.

Keywords: sofosbuvir ombitasvir paritaprevir ribavirin ritonavir hcv gt 4 experienced egyptian patients cirrhotic non-cirrhotic
use of electroconvulsive therapy (ect) in chronic, severe, treatment resistant posttraumatic stress disorder

Conditions: Posttraumatic Stress Disorder

Summary: post traumatic stress disorder is a chronic debilitating illness and few treatment options have demonstrated effectiveness. the study will look at the use of electroconvulsive therapy for the treatment of post traumatic stress disorder in patients who have not responded to multiple antidepressants or cognitive behavioral therapy.


Eligibility criteria:
inclusion criteria: * diagnosis of ptsd * treatment resistance to 4 different antidepressants from 3 different classes * treatment resistance to cbt * severe ptsd exclusion criteria: * significant substance abuse * pregnancy * history of traumatic brain injury * unstable comorbid medical illness * organic brain syndrome

Keywords: posttraumatic stress disorder electroconvulsive therapy medication refractoriness
cancer associated thrombosis : what is the proportion of patients ineligible to a study as caravaggio

Conditions: Venous Thromboembolism; Cancer

Summary: venous thromboembolism is a common and fatal disease closely related to cancer. the therapeutic challenge is major due to the high risk of recurrent thromboembolism and bleeding in patients with cancer. guidelines recommend the use of low molecular-weight heparin for the treatment of cancer-associated venous thromboembolism (cat) at least for 3 to 6 months of treatment. however, recent advances through the results of several therapeutic trials such as caravaggio (nct03045406) open the door to the use of direct oral anticoagulants (doacs) as first-line therapy. nevertheless, extrapolation of its results may be limited owing to a large number of inclusion and exclusion criteria, which may have selected a reduced population. the proportion of patients admitted with acute cat who may not eligible to a trial as caravaggio is unknown.

the aim of this study si to assess this proportion in a retrospective multicenter study, of patients admitted for acute cancer-associated venous thromboembolism (cat).

Eligibility criteria:
inclusion criteria: consecutive patients with a newly diagnosed, objectively confirmed: * symptomatic or unsuspected deep vein thrombosis (dvt) (any location) * symptomatic or unsuspected pulmonary embolism (pe) consecutive patients with any type of cancer whose primary brain tumor or known intracerebral metastases and acute leukemia that meets at least one of the following: * active cancer defined as diagnosis of cancer within six months or receiving treatment for cancer or any treatment for cancer or recurrent locally advanced or metastatic cancer. * cancer diagnosed within 2 years. exclusion criteria: * pregnant women or breast feeding

Keywords: cancer thrombosis epidemiology cancer-associated venous thromboembolism (cat) venous thromboembolic event